View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 30, 2020updated 12 Jul 2022 11:34am

AstraZeneca’s Fasenra eliminates oral corticosteroids use in asthma trial

AstraZeneca has reported that the PONENTE Phase IIIb trial showed Fasenra (benralizumab) eliminated the use of maintenance oral corticosteroids (OCS) in a majority of OCS-dependent asthma patients.

AstraZeneca has reported that the PONENTE Phase IIIb trial showed Fasenra (benralizumab) eliminated the use of maintenance oral corticosteroids (OCS) in a majority of OCS-dependent asthma patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Developed by AstraZeneca and in-licensed from Kyowa Kirin subsidiary BioWa, Fasenra is a monoclonal antibody that attaches directly to IL-5 receptor alpha on eosinophils.

It attracts natural killer cells to induce rapid and near-complete depletion of eosinophils through apoptosis.

The multi-centre, open-label, single-arm trial was conducted on 600 patients in Europe, North America, South America, and Taiwan.

It evaluated the efficacy and safety of reducing daily OCS use after initiation of a 30mg dose of Fasenra administered subcutaneously (SC) in participants.

The subjects included adult patients with severe eosinophilic asthma on high-dose inhaled corticosteroids (ICS), plus long-acting beta2-agonist (LABA) and long-term use of OCS therapy with or without additional asthma controllers.

The treatment period had a four-week induction phase with no OCS adjustments, a variable OCS tapering phase, and an ongoing 24 to 32-week maintenance phase.

In the trial’s first primary endpoint, 62% of patients achieved complete elimination of daily OCS use.

About 81% of patients achieved complete elimination or were able to reduce their daily OCS dose to 5mg or less when the further reduction was not possible owing to adrenal insufficiency, thus meeting the second primary endpoint.

The results were sustained for at least four weeks while maintaining asthma control.

AstraZeneca BioPharmaceuticals R&D executive vice-president Mene Pangalos said: “Around 13.5 million people worldwide with severe asthma currently rely on oral corticosteroids to control exacerbations and prevent hospitalisations.

“These data further support Fasenra’s clinical profile in eliminating oral corticosteroid use across a broader population of severe asthma patients.”

Frequent or chronic use of OCS can lead to serious adverse effects in asthma patients.

Last month, AstraZeneca reported positive results from the Phase III OSTRO trial of Fasenra to treat patients with chronic rhinosinusitis with nasal polyps.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena